Improved Access to Biosimilar Drugs in Medicare Advantage
This act aims to improve access to more affordable biosimilar drugs for individuals enrolled in the Medicare Advantage program. It introduces new evaluation criteria for insurance plans, rewarding those that encourage the use of biosimilars over more expensive original drugs. This could lead to greater choice and potentially lower treatment costs for patients, without compromising care quality.
Key points
Medicare Advantage plans will be rated based on their access to biosimilar drugs, potentially affecting their overall star rating.
Evaluations will consider whether biosimilars are on the drug list, their cost relative to original products, and how their use is managed.
The goal is to ensure patients have equal access to effective treatment options while promoting more affordable alternatives.
These changes could lead to reduced healthcare costs for patients and the healthcare system.
Expired
Citizen Poll